ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0446

The Burden of Coronary Artery Calcification in ANCA-Associated Vasculitis

Anushri Parakh1, Claire Cook1, Xiaoqing Fu1, sandeep hedgire1, John Stone2, Hyon Choi3, Michael Lu1 and Zachary Wallace1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 3MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis, Cardiovascular

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: ANCA-associated vasculitis (AAV) is associated with an increased risk of cardiovascular (CV) disease, with MPO- AAV conferring a higher risk of CV events than PR3-ANCA+ AAV1,2. The coronary artery calcium (CAC) score is a measure of atherosclerotic burden and associated with future CV events in the general population. We investigated the burden of CAC in AAV.

Methods: We identified patients in the 2002-2019 Mass General Brigham (MGB) AAV Cohort with a non-contrast computed tomography (CT) scan of the chest performed for clinical purposes. The 2002-2019 MGB AAV Cohort includes consecutive patients who are PR3- or MPO-ANCA+. Patients with prior coronary intervention or bypass surgery were excluded. CAC scores were calculated using the Agatston method. We determined age, sex, and race-standardized percentiles of CAC scores using the Multi-Ethnic Study of Atherosclerosis (MESA) tool. We assessed the association of baseline features of AAV disease activity with CAC using linear regression. We determined the differences in CAC among MPO- vs PR3-ANCA+ AAV using t-tests and linear regression. When comparing CAC scores, we adjusted for age and sex.

Results: Of 179 patients, the mean age was 65 years, 58% were female, and 73% were MPO-ANCA+. At diagnosis, 45% had hypertension, 29% had hyperlipidemia, 15% had diabetes, and 57% were ever smokers. The mean baseline eGFR was 44 ml/min. MPO-ANCA+ patients were older than PR3-ANCA+ patients (67 vs 59 yrs); a similar proportion were female (57% vs 60%). The mean CAC score was 398 (±865) and 120 (67%) patients had calcification. In the entire cohort, the mean MESA percentile was 44 (±37). There was an inverse association of eGFR at AAV diagnosis with MESA percentile (β -0.31 (95%CI -0.57 to -0.06) / 1ml/min, p=0.02). There was a trend toward association of baseline ESR with MESA percentile (β 0.14 (95%CI -0.01 to 0.28) / 1mm/hr increase, p=0.06). Baseline BVAS/WG and CRP were not associated with MESA percentiles. The mean days from AAV diagnosis to the CT used to measure CAC was similar in MPO- and PR3-ANCA+ patients (1530 vs 1588 days, p=0.8). The mean MESA percentile was higher among MPO- vs PR3-ANCA+ AAV (48 (37) vs 32 (34), difference +16.3 [95% CI 4.1-28.4], p=0.009). The mean CAC score was greater in MPO- vs PR3-ANCA+ AAV (adjusted difference +293 [95%CI 24-562], p=0.03).

Conclusion: Coronary artery calcification is common in AAV and associated with renal function and the inflammatory state. Compared with PR3-ANCA+, CAC burden in MPO-ANCA+ was greater than expected based on age, sex, and race. These findings support prior observations that MPO-ANCA+ AAV has a higher risk for CVD. The overall burden of CAC was not greater than expected for age, sex, and race. This has been observed in other inflammatory conditions (e.g., HIV) where non-calcified plaque is a strong contributor to CV risk2. Prospective studies are needed to comprehensively investigate both calcified and non-calcified plaque among patients to elucidate factors driving CV risk.

1Arthritis Care Res 2011;63:588
2
Rheumatology 2020;59:2308
3
J Am Heart Assoc. 2021;10:e019291

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: A. Parakh, None; C. Cook, None; X. Fu, None; s. hedgire, None; J. Stone, Horizon Theraputics, Sanofi, Amgen, Argenx, Bristol-Myers Squibb(BMS), Chemocentryx, Kyverna, Novartis, Palleon Pharmaceuticals, PPD, Q32, Star Therapeutics, Roche, Mirabio, Spruce Biosciences, Steritas, Zenas; H. Choi, Horizon, Allena, LG, Protalix; M. Lu, AstraZeneca, MedImmune, Kowa; Z. Wallace, Sanofi, Bristol-Myers Squibb(BMS), Zenas Biopharma, Shionogi, Horizon.

To cite this abstract in AMA style:

Parakh A, Cook C, Fu X, hedgire s, Stone J, Choi H, Lu M, Wallace Z. The Burden of Coronary Artery Calcification in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-burden-of-coronary-artery-calcification-in-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-burden-of-coronary-artery-calcification-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology